Celcuity Inc. Reports Unexpected Quarterly Loss, Stock Declines
Celcuity Inc., a biotechnology company, reported a quarterly loss of $0.93 per share, exceeding market expectations and causing its stock price to decline.
2 minutes to read
Celcuity Inc. Secures $248.7 Million in Financing Amidst Breakthrough in Breast Cancer Treatment
Celcuity Inc. has made significant financial moves, including a $248.7 million debt and stock offering, to support its clinical trials and development of targeted therapies for breast cancer and other solid tumors.
2 minutes to read
Celcuity Inc. Poised for Breakthrough as VIKTORIA-1 Trial Results Loom
Celcuity Inc., a clinical-stage biotech company, is poised for a potential breakthrough with the upcoming announcement of its phase 3 VIKTORIA-1 trial results, which could redefine treatment paradigms for advanced breast cancer.
3 minutes to read
Celcuity Inc. Projects $2 Billion Revenue for Gedatolisib as Phase 3 Trials Progress
Celcuity Inc. is poised for growth with a $2 billion peak revenue potential for its flagship drug gedatolisib, a promising development in the biotechnology industry.
2 minutes to read